These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33677779)

  • 1. Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
    Takahashi M; Inoue K; Mukai H; Yamanaka T; Egawa C; Miyoshi Y; Sakata Y; Muramoto K; Ikezawa H; Matsuoka T; Tsurutani J
    Breast Cancer; 2021 Jul; 28(4):945-955. PubMed ID: 33677779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
    Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
    Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
    BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
    Watanabe J; Saito M; Horimoto Y; Nakamoto S
    Breast Cancer Res Treat; 2020 May; 181(1):211-220. PubMed ID: 32249370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
    Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
    BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types.
    Morisaki T; Kashiwagi S; Asano Y; Goto W; Takada K; Ishihara S; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    World J Surg Oncol; 2021 Nov; 19(1):324. PubMed ID: 34775950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
    Sata A; Fukui R; Miyagawa Y; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Imamura M; Miyoshi Y
    Anticancer Res; 2020 Jul; 40(7):4147-4156. PubMed ID: 32620664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
    Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
    Oba T; Maeno K; Ono M; Ito T; Kanai T; Ito KI
    Anticancer Res; 2021 Jan; 41(1):445-452. PubMed ID: 33419842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
    Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
    Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit.
    Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T
    Anticancer Res; 2021 Jun; 41(6):3109-3119. PubMed ID: 34083304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
    Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
    Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
    Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
    Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Morisaki T; Kouhashi R; Yabumoto A; Tanaka S; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2020 Jun; 40(6):3345-3354. PubMed ID: 32487630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.
    Koyama Y; Kawai S; Uenaka N; Okazaki M; Asaoka M; Teraoka S; Ueda AI; Miyahara K; Kawate T; Kaise H; Yamada K; Ishikawa T
    Cancer Diagn Progn; 2021; 1(5):435-441. PubMed ID: 35403160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
    Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
    Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
    Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
    Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
    Nakamoto S; Watanabe J; Ohtani S; Morita S; Ikeda M
    BMC Cancer; 2022 Jan; 22(1):31. PubMed ID: 34980019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
    Tsurutani J; Sakata Y; Matsuoka T
    Breast Cancer; 2019 Mar; 26(2):235-243. PubMed ID: 30324551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.